看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | -0.5x - -0.6x | -0.5x |
| Selected Fwd EBITDA Multiple | 0.1x - 0.1x | 0.1x |
| Fair Value | ₪0.013 - ₪0.013 | ₪0.013 |
| Upside | -20.8% - -17.3% | -19.0% |
| Benchmarks | Ticker | Full Ticker |
| Entera Bio Ltd. | ENTX | NasdaqCM:ENTX |
| Pluri Inc. | PLUR | TASE:PLUR |
| XTL Biopharmaceuticals Ltd. | XTLB | TASE:XTLB |
| BioLineRx Ltd. | BLRX | TASE:BLRX |
| Scinai Immunotherapeutics Ltd. | SCNI | NasdaqCM:SCNI |
| Can-Fite BioPharma Ltd. | CANF | TASE:CANF |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| ENTX | PLUR | XTLB | BLRX | SCNI | CANF | ||
| NasdaqCM:ENTX | TASE:PLUR | TASE:XTLB | TASE:BLRX | NasdaqCM:SCNI | TASE:CANF | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | -8.0% | 10.3% | NM | 62.3% | 32.3% | 0.7% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -12058.8% | -32611.6% | 0.0% | -310.8% | -2002.6% | -1327.9% | |
| Prior Fiscal Year | NA | -9367.2% | NA | -868.0% | NA | -1100.9% | |
| Latest Fiscal Year | -5270.2% | -6719.3% | NA | -54.2% | NA | -1205.2% | |
| Latest Twelve Months | -5270.2% | -3166.4% | NA | -54.2% | -1540.7% | -1205.2% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 395.32x | 60.81x | 201.05x | 0.20x | 4.26x | 10.06x | |
| EV / LTM EBITDA | -7.5x | -1.9x | NA | -0.4x | -0.3x | -0.8x | |
| EV / LTM EBIT | -7.5x | -1.9x | -5.9x | -0.3x | -0.2x | -0.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -7.5x | -1.1x | -0.3x | ||||
| Historical EV / LTM EBITDA | -2.0x | -0.8x | -0.1x | ||||
| Selected EV / LTM EBITDA | -0.5x | -0.5x | -0.6x | ||||
| (x) LTM EBITDA | (8) | (8) | (8) | ||||
| (=) Implied Enterprise Value | 4 | 4 | 5 | ||||
| (-) Non-shareholder Claims * | 8 | 8 | 8 | ||||
| (=) Equity Value | 12 | 12 | 12 | ||||
| (/) Shares Outstanding | 3,893.2 | 3,893.2 | 3,893.2 | ||||
| Implied Value Range | 0.00 | 0.00 | 0.00 | ||||
| FX Rate: USD/ILS | 0.3 | 0.3 | 0.3 | Market Price | |||
| Implied Value Range (Trading Cur) | 0.01 | 0.01 | 0.01 | 0.02 | |||
| Upside / (Downside) | -29.5% | -28.2% | -26.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | ENTX | PLUR | XTLB | BLRX | SCNI | CANF | |
| Enterprise Value | 72 | 42 | 9 | 6 | 2 | 9 | |
| (+) Cash & Short Term Investments | 9 | 21 | 2 | 20 | 1 | 8 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Debt | (0) | (29) | 0 | (15) | (1) | (0) | |
| (-) Other Liabilities | 0 | (5) | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 80 | 29 | 11 | 10 | 2 | 17 | |
| (/) Shares Outstanding | 45.4 | 7.8 | 881.4 | 2,232.6 | 0.9 | 3,893.2 | |
| Implied Stock Price | 1.76 | 3.73 | 0.01 | 0.00 | 1.92 | 0.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 0.27 | 0.27 | 0.27 | 1.00 | 0.27 | |
| Implied Stock Price (Trading Cur) | 1.76 | 13.79 | 0.05 | 0.02 | 1.92 | 0.02 | |
| Trading Currency | USD | ILS | ILS | ILS | USD | ILS | |
| FX Rate to Reporting Currency | 1.00 | 0.27 | 0.27 | 0.27 | 1.00 | 0.27 | |